JIANGSU HENGRUI PHARMACEUT

Jiangsu Hengrui’s new PD‑1 inhibitor promises higher survival rates and better recovery for peri‑operative gastric cancer patients, driving strong market share and premium reimbursement in China.

Jiangsu Hengrui Pharmaceutical boosts investor confidence with share‑buybacks and a new postoperative pain drug, riding China’s rising innovation‑drug momentum.

Jiangsu Hengrui’s aggressive share‑buyback and China’s new biopharma reimbursement reforms signal a growing investor confidence, positioning the company for robust growth and value creation amid supply‑chain resilience and regulatory evolution.